Kamada (KMDA) Share-based Compensation (2012 - 2026)
Kamada's (KMDA) quarterly Share-based Compensation came in at $720000.0 in Q2 2026, up 657.89% on a YoY basis from $95000.0 in Q2 2025, and down 10.0% quarter-over-quarter from $800000.0 in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) Share-based Compensation (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Share-based Compensation for 15 consecutive years, with $720000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 657.89% year-over-year to $720000.0; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (up 213.07% YoY), and the FY2025 full-year result was $845000.0, down 3.32% from the prior year.
- Share-based Compensation retreated to $720000.0 in Q2 2026 per KMDA's latest filing, from $800000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.6 million in Q1 2023 and bottomed at $25000.0 in Q4 2022.
- Historically, Share-based Compensation has averaged $600666.7 across 5 years, with a median of $238000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 10564.0% in 2023, then tumbled 94.71% in 2024.
- Over 5 years, Share-based Compensation stood at $25000.0 in 2022, then soared by 10564.0% to $2.7 million in 2023, then sank by 94.71% to $141000.0 in 2024, then jumped by 148.94% to $351000.0 in 2025, then surged by 105.13% to $720000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $720000.0, $800000.0, and $351000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 720,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 720,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 2.67 Mn |
| Sep 30, 2023 | 312,000.00 |
| Jun 30, 2023 | 214,000.00 |
| Mar 31, 2023 | 3.58 Mn |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 366,000.00 |
| Jun 30, 2022 | 376,000.00 |
| Mar 31, 2022 | 174,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Sep 30, 2021 | 134,000.00 |